S-1 - Onconetix, Inc. (0001782107) (Filer)

D - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

10-Q - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

8-K - Onconetix, Inc. (0001782107) (Filer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

3 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

4 - Onconetix, Inc. (0001782107) (Issuer)

3/A - Onconetix, Inc. (0001782107) (Issuer)

Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring develop

CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million

CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and deliver

CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, today announced that its wholly owned subsidiary, Proteomedix AG ("Proteomedix") has  signed a licensing agreement, with Immunovia AB, a pancreatic cancer diagnostics company based in Lund, Sweden. Under the terms of the agreement, Proteomedix will provide Immunovia with master cells required to produce antibodies related to three of the five biomarkers included in the PancreaSure test and a license for key intellectual property

CINCINNATI, July 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates, today announced that they have entered into a definitive merger agreement (the "Merger Agreement"). Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We continue to believe that the proposed transaction with Ocuvex, which brings a pipeline of commercial and late clinical stage ophthalmic assets, will bring significant value for our stockholders." Anthony W. Amato, Chairman and CEO of Ocuvex, commented

CINCINNATI, Ohio, June 16, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today reported that on June 11, 2025, the Company received a decision from the Nasdaq Hearings Panel granting the Company's request for continued listing on The Nasdaq Stock Market, subject to the Company demonstrating compliance with the Nasdaq Listing Rule 5550(a)(2) (the "Periodic Filing Listing Rule") by June 13, 2025 and the  Nasdaq Listing Rule 5250(c)(1) (the "Bid Price Listing Rule") on or before June 30, 2025. The

CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved a proposal to effect a reverse split, which was voted on at the Company's 2025 special meeting of stockholders (the "Special Meeting") held on May 30, 2025, and that its Board of Directors (the "Board of Directors" or "Board") approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on June 1

Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on May 20, 2025 indicating that the Company's failure to file its Quarterly Report on Form 10-Q for the three months ended March 31, 2025 (the "10-Q") is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange C

Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) (the "Company") announced that it received a Staff delisting letter from The Nasdaq Capital Market ("Nasdaq") on April 24, 2025 indicating that the Company's failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024 is in violation of Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule").   This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.  As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission

CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex. Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late c

Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

SC 13G - Onconetix, Inc. (0001782107) (Subject)

SC 13D - Onconetix, Inc. (0001782107) (Subject)

SC 13D - Onconetix, Inc. (0001782107) (Subject)

SC 13D - Onconetix, Inc. (0001782107) (Subject)

SC 13G - Onconetix, Inc. (0001782107) (Subject)

SC 13G/A - Onconetix, Inc. (0001782107) (Subject)